Researchers from Mass General Brigham will present research discoveries and outcomes from clinical trials in cancer at the ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

Phase III progression-free survival data were positive for first-line Braftovi in first-line combination therapy for mCRC.

Sara M. Tolaney, MD, MPH, highlights a transformative year for breast cancer research at this year’s ASCO Annual Meeting.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that ten abstracts have been accepted for presentation at ...

Pfizer Inc. today announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab ...

ASCO 2025 will showcase cutting-edge advancements in precision medicine, artificial intelligence, and biomarker-driven ...

What is worth more: your AI biometric fingerprint or the money stored in your bank accounts? What happens when a leader does not verify the accuracy of artificial intelligence results? These questions ...

The abstract title is now publicly available on the ASCO Meeting website. It can be accessed by visiting https://meetings.asco.org, navigating to the Posters section, and locating the abstract ...

The ASCO annual meeting is widely considered one ... 200 professional sessions and the presentation of more than 5,000 abstracts. STAT reporters will be on the ground, delivering breaking oncology ...

Pasithea Therapeutics Corp. has announced the acceptance of an abstract for a poster presentation at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting, scheduled for May 30 ...